Dr. Socinski on Improvements to Immunotherapy for Lung Cancer

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

One of the ways immunotherapy can be improved is by the selection of the patients, explains Socinski. There is evidence that demonstrates that patients who strongly stain for PD-L1 have better outcomes.

There is also some encouraging data from the KEYNOTE-021 trial for combining immunotherapy with chemotherapy. Combining immunotherapy agents could have potential but it creates the risk for higher toxicities, states Socinski.